...
首页> 外文期刊>The Journal of biological chemistry >Identification of Orthosteric and Allosteric Site Mutations in M2 Muscarinic Acetylcholine Receptors That Contribute to Ligand-selective Signaling Bias
【24h】

Identification of Orthosteric and Allosteric Site Mutations in M2 Muscarinic Acetylcholine Receptors That Contribute to Ligand-selective Signaling Bias

机译:鉴定与配体选择性信号偏置有助于配体选择性信号偏差的M2毒蕈酰乙酰胆碱受体中的矫形和颠振突变

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Muscarinic acetylcholine receptors contain at least one allosteric site that is topographically distinct from the acetylcholine, orthosteric binding site. Although studies have investigated the basis of allosteric modulation at these receptors, less is known about putative allosteric ligands that activate the receptor in their own right. We generated M2 muscarinic acetylcholine receptor mutations in either the orthosteric site in transmembrane helices 3 and 6 (TM3 and -6) or part of an allosteric site involving the top of TM2, the second extracellular (E2) loop, and the top of TM7 and investigated their effects on the binding and function of the novel selective (putative allosteric) agonists (AC-42 (4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)piperidine HCl), 77-LH-28-1 (1-(3-(4-butyl-1-piperidinyl)propyl)-3,3-dihydro-2(1H)-quinolinone), and N-desmethylclozapine) as well as the bitopic orthosteric/allosteric ligand, McN-A-343 (4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium). Four classes of agonists were identified, depending on their response to the mutations, suggesting multiple, distinct modes of agonist-receptor interaction. Interestingly, with the exception of 77-LH-28-1, allosteric site mutations had no effect on the affinity of any of the agonists tested, but some mutations in the E2 loop influenced the efficacy of both orthosteric and novel selective agonists, highlighting a role for this region of the receptor in modulating activation status. Two point mutations (Y1043.33A (Ballesteros and Weinstein numbers in superscript) in the orthosteric and Y177A in the allosteric site) unmasked ligand-selective and signaling pathway-selective effects, providing evidence for the existence of pathway-specific receptor conformations. Molecular modeling of 77-LH-28-1 and N-desmethylclozapine yielded novel binding poses consistent with the possibility that the functional selectivity of such agents may arise from a bitopic mechanism.
机译:肌肉素乙酰胆碱受体含有至少一个与乙酰胆碱,矫形粘合位点进行地拓扑不同的颠覆性位点。虽然研究已经研究了这些受体的变构调节的基础,但是关于推定的颠覆配体,较少的令人满意的颠覆式配体,其在自己的权利中激活受体。我们在跨越晶体螺旋3和6(TM3和-6)中的末端部位中产生的M2毒蕈碱乙酰胆碱受体突变或涉及TM2的顶部的颠覆部位的一部分,第二个细胞外(E2)环,以及TM7的顶部研究了对新型选择性(推定颠振)激动剂(AC-42(4-正丁基-1-(4-(2-甲基苯基)-4-氧代-1-丁基-1-丁基)哌啶HCl)的结合和功能的影响,77-LH-28-1(1-(3-(4-丁基-1-哌啶基)丙基)-3,3-二氢-2(1H) - 喹啉酮)和N-去甲基苄啶,以及比特普克矫形/变构配体,MCN-A-343(4-(M-氯苯基 - 氨基甲酰氧基)-2-丁炔基三甲基铵)。确定了四种激动剂,取决于它们对突变的响应,表明多种不同的激动剂受体相互作用。有趣的是,除了77-LH-28-1的例外,颠振站突变对任何测试的任何激动剂的亲和力没有影响,但E2环中的一些突变影响了矫形和新颖的选择性激动剂的功效,突出显示在调制激活状态时对受体的该区域的作用。两个点突变(y1043.33a(y1043.33a(alperscoss)在颠覆部位中的正向和y177a中的y1043.33a))未掩蔽配体选择性和信号传导途径选择作用,为存在途径特异性受体构象提供证据。 77-LH-28-1和N-去除甲基苄萘滨的分子模型产生了新的结合姿势,这与这些试剂的功能选择性可能来自比特缺陷机制可能的可能性一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号